6 assets in Chordoma

Therapeutic assets addressing Chordoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Nivolumab Chordoma	Sarcoma Oncology Research Center, LLC	P2	B (62)
Ipilimumab Chordoma	National Cancer Institute (NCI)	P2	CCC (53)
Atezolizumab Chordoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Fludeoxyglucose Chordoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Tiragolumab Chordoma	National Cancer Institute (NCI)	P1/2	CCC (48)
Zoledronate Chordoma	University of Florida	P1/2	CCC (48)